Radiation Therapy and 5-Fluorouracil in Pancreatic Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 10717227.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Combination chemotherapy has not been shown to be superior to single-agent 5-fluorouracil (5-FU) in the treatment of metastatic pancreatic cancer. Initial studies from Duke University suggest a role for radiation in the management of locally unresectable presentations of this disease. In vivo studies showed that 5-FU could act as a radiation sensitizer. This concept was subsequently tested in a randomized trial by the Gastrointestinal Tumor Study Group (GITSG). In their studies, combined modality therapy using radiation and 5-FU-based chemotherapy prolonged survival in both adjuvant and locally unresectable settings and remains as a standard therapeutic option for appropriately selected patients. Variations on this approach designed to potentiate 5-FU efficacy are under active clinical investigation. This review discussed past and current studies involving 5-FU as well as other agents currently of interest.